ES2324281T3 - Eteres de dicarboxilato de calcio, procedimientos de fabricacion de los mismos. - Google Patents

Eteres de dicarboxilato de calcio, procedimientos de fabricacion de los mismos. Download PDF

Info

Publication number
ES2324281T3
ES2324281T3 ES01900037T ES01900037T ES2324281T3 ES 2324281 T3 ES2324281 T3 ES 2324281T3 ES 01900037 T ES01900037 T ES 01900037T ES 01900037 T ES01900037 T ES 01900037T ES 2324281 T3 ES2324281 T3 ES 2324281T3
Authority
ES
Spain
Prior art keywords
crystalline form
acid
methyl
monocalcic
hexyloxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES01900037T
Other languages
English (en)
Spanish (es)
Inventor
Howard Yoshihisa Ando
Donald Eugene Butler
Gary Jay Dozeman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Warner Lambert Co LLC
Original Assignee
Warner Lambert Co LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co LLC filed Critical Warner Lambert Co LLC
Application granted granted Critical
Publication of ES2324281T3 publication Critical patent/ES2324281T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/125—Saturated compounds having only one carboxyl group and containing ether groups, groups, groups, or groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/305—Saturated compounds containing more than one carboxyl group containing ether groups, groups, groups, or groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
ES01900037T 2000-01-25 2001-01-11 Eteres de dicarboxilato de calcio, procedimientos de fabricacion de los mismos. Expired - Lifetime ES2324281T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17782300P 2000-01-25 2000-01-25
US177823P 2000-01-25

Publications (1)

Publication Number Publication Date
ES2324281T3 true ES2324281T3 (es) 2009-08-04

Family

ID=22650106

Family Applications (1)

Application Number Title Priority Date Filing Date
ES01900037T Expired - Lifetime ES2324281T3 (es) 2000-01-25 2001-01-11 Eteres de dicarboxilato de calcio, procedimientos de fabricacion de los mismos.

Country Status (39)

Country Link
EP (1) EP1259474B1 (enExample)
JP (1) JP4750995B2 (enExample)
KR (1) KR20020073182A (enExample)
CN (1) CN1395555A (enExample)
AP (1) AP2002002587A0 (enExample)
AR (1) AR029436A1 (enExample)
AT (1) ATE431326T1 (enExample)
AU (1) AU2214001A (enExample)
BG (1) BG106851A (enExample)
BR (1) BR0107763A (enExample)
CA (1) CA2397960C (enExample)
CO (1) CO5261537A1 (enExample)
CZ (1) CZ20022474A3 (enExample)
DE (1) DE60138686D1 (enExample)
DK (1) DK1259474T3 (enExample)
DZ (1) DZ3239A1 (enExample)
EA (1) EA004862B1 (enExample)
EE (1) EE200200404A (enExample)
ES (1) ES2324281T3 (enExample)
GE (1) GEP20053428B (enExample)
GT (1) GT200100015A (enExample)
HN (1) HN2001000011A (enExample)
HU (1) HUP0204422A3 (enExample)
IL (1) IL150541A0 (enExample)
IS (1) IS6442A (enExample)
MA (1) MA26867A1 (enExample)
MX (1) MXPA02007223A (enExample)
NO (1) NO20023526L (enExample)
NZ (1) NZ519550A (enExample)
OA (1) OA12166A (enExample)
PA (1) PA8510601A1 (enExample)
PE (1) PE20011064A1 (enExample)
PL (1) PL357076A1 (enExample)
SK (1) SK10622002A3 (enExample)
SV (1) SV2002000290A (enExample)
TN (1) TNSN01013A1 (enExample)
UY (1) UY26550A1 (enExample)
WO (1) WO2001055078A1 (enExample)
ZA (1) ZA200205880B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1481962A1 (en) * 1997-12-12 2004-12-01 Warner-Lambert Company LLC New cholesterolemia-lowering carboxyalkylether compound
WO2004017952A1 (en) * 2002-08-22 2004-03-04 Warner-Lambert Company Llc Method of treating osteoarthritis
CN101163668A (zh) * 2005-04-19 2008-04-16 卫材R&D管理有限公司 双[(2s)-3-[3-(2s)-3-(4-氯-2-氰基苯氧基)-2-氟丙氧基]苯基]-2-异丙氧基丙酸]钙及其中间体
US7816405B2 (en) 2005-04-19 2010-10-19 Eisai R&D Management Co., Ltd. Calcium bis [(2S)-3-[3-[(2S)-3-(4-chloro-2-cyanophenoxy)-2-fluoropropoxy]phenyl ]-2-isopropoxypropionate] and intermediate thereof
WO2016077832A2 (en) * 2014-11-14 2016-05-19 Gemphire Therapeutics Inc. PROCESSES AND INTERMEDIATES FOR PREPARING α,ω-DICARBOXYLIC ACID-TERMINATED DIALKANE ETHERS
CA3059073A1 (en) * 2017-04-18 2018-10-25 Daniela Carmen Oniciu Gemcabene, pharmaceutically acceptable salts thereof, compositions thereof and methods of use therefor
CN113396138A (zh) * 2018-10-18 2021-09-14 燿石治疗公司 吉卡宾、其药学上可接受的盐、其组合物和其使用方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5648387A (en) * 1995-03-24 1997-07-15 Warner-Lambert Company Carboxyalkylethers, formulations, and treatment of vascular diseases
NZ503982A (en) 1997-12-12 2002-03-28 Warner Lambert Co Statin-carboxyalkylether combinations useful for treating vascular disorders and diabetes mellitus

Also Published As

Publication number Publication date
JP2003520835A (ja) 2003-07-08
UY26550A1 (es) 2001-08-27
CA2397960C (en) 2008-09-09
GT200100015A (es) 2001-10-19
EP1259474A1 (en) 2002-11-27
WO2001055078A1 (en) 2001-08-02
NO20023526D0 (no) 2002-07-24
DE60138686D1 (de) 2009-06-25
MA26867A1 (fr) 2004-12-20
SK10622002A3 (sk) 2003-07-01
AU2214001A (en) 2001-08-07
EA004862B1 (ru) 2004-08-26
DZ3239A1 (fr) 2001-08-02
GEP20053428B (en) 2005-01-25
MXPA02007223A (es) 2002-11-29
PL357076A1 (en) 2004-07-12
EA200200641A1 (ru) 2002-12-26
KR20020073182A (ko) 2002-09-19
JP4750995B2 (ja) 2011-08-17
EE200200404A (et) 2003-10-15
PE20011064A1 (es) 2001-10-22
CZ20022474A3 (cs) 2003-06-18
EP1259474B1 (en) 2009-05-13
ZA200205880B (en) 2003-07-23
ATE431326T1 (de) 2009-05-15
SV2002000290A (es) 2002-07-16
IS6442A (is) 2002-06-25
IL150541A0 (en) 2003-02-12
CA2397960A1 (en) 2001-08-02
PA8510601A1 (es) 2002-08-26
CO5261537A1 (es) 2003-03-31
HUP0204422A2 (en) 2003-05-28
NZ519550A (en) 2003-11-28
BR0107763A (pt) 2002-11-12
DK1259474T3 (da) 2009-07-20
AP2002002587A0 (en) 2002-09-30
AR029436A1 (es) 2003-06-25
BG106851A (en) 2003-01-31
CN1395555A (zh) 2003-02-05
TNSN01013A1 (fr) 2005-11-10
HUP0204422A3 (en) 2003-08-28
NO20023526L (no) 2002-08-27
HN2001000011A (es) 2001-06-13
OA12166A (en) 2003-11-07

Similar Documents

Publication Publication Date Title
EP2244712B1 (en) In vivo studies of crystalline forms of meloxicam
EP2870163B1 (en) Pharmaceutical compositions comprising rifaximin and amino acids, preparation method and use thereof
AU2017336889B2 (en) Polymorphic form of kinase inhibitor compound, pharmaceutical composition containing same, and preparation method therefor and use thereof
SK286245B6 (sk) Farmaceutická kompozícia obsahujúca ziprasidon a spôsob výroby veľkých kryštálov monohydrátu hydrochloridu ziprasidonu
JP2016509031A (ja) トレラグリプチンの固形形式及びその製造方法と用途
RS56464B1 (sr) Oblik iv ivabradin hidrohlorida
CN101597272B (zh) 艾拉莫德的钾盐化合物,其制备方法和药物应用
ES2324281T3 (es) Eteres de dicarboxilato de calcio, procedimientos de fabricacion de los mismos.
US7141608B2 (en) Calcium dicarboxylate ethers, methods of making same, and treatment of vascular disease and diabetes therewith
CN106279127B (zh) 阿法替尼酸加成盐及其晶型、其制备方法及药物组合物
JP4015954B2 (ja) トシル酸スプラタスト結晶
TW201143761A (en) Tablet formulation of ezatiostat
KR20080104063A (ko) 치환 페닐알칸산의 신규 결정 및 제조 방법
JP7640815B2 (ja) 生理活性ペプチド含有製剤
US11795180B2 (en) Formulation of a pan-JAK inhibitor
JP2020522472A (ja) Ｐｋｃ阻害剤の固体状態形態
JP5589097B2 (ja) ダサチニブ多結晶体、並びにその調製方法及び薬物組成物
JP2025511126A (ja) ケノデオキシコール酸ナトリウムの形態及び組成物
WO2025179296A1 (en) Crystalline forms of nu-3 and uses thereof
TW202440585A (zh) MDM2-p53抑制劑之晶型及醫藥組合物
Murti On the preparation and characterization of water-soluble choline salts of carboxylic acid drugs
HK40036995A (en) Crystals of glycyrrhizic acid derivatives, crystalline compositions, pharmaceutical compositions and uses thereof
HK40052085B (en) Pharmaceutical compound, the method of its making and use as medicinal agent
HK40052085A (en) Pharmaceutical compound, the method of its making and use as medicinal agent
Injety Formulation of a nevirapine co-crystal as a liquid dosage form